Qiagen N.V. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Qiagen N.V. with three other
pharmaceutical manufacturers in Europe:
Recordati Industria Chimica e Farmaceutica SpA
sales of 1.48 billion Euros [US$1.76 billion]
of which 83%
was Specialty & Primary care),
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
(507.79 billion Hungarian Forints [US$1.67 billion]
of which 78%
was Pharmaceutical Manufacturing and Sale), and
Swedish Orphan Biovitrum AB (publ)
based in SWEDEN
(14.25 billion Swedish Kronor [US$1.62 billion]
of which 100%
Qiagen N.V. reported sales of 1.37 billion Euro (US$1.62 billion)
December of 2019.
increase of 7.1%
versus 2018, when the company's sales were 1.27 billion Euro.
Sales at Qiagen N.V. have increased during each of the previous five years
(and since 2014, sales have increased a total of 34%).
Sales of Consumables and Related Revenues saw an increase
8.5% in 2019, from
1.12 billion Euro to 1.21 billion Euro.
Not all segments of Qiagen N.V. experienced an increase in sales in 2019:
sales of Instrumentation fell 2.6% to 154.13 million Euro.